Immunotherapy

Panel 06 - The Evolving Role of Immunotherapy in Breast Cancer Treatment

9/16/2019
10:45 AM - 12:00 PM
Location: Room W196

Session Type: Panel
1.25 AMA PRA Category 1 Credits™
1.25 CAMPEP Credits
1.5 MDCB Credits

Clinical trials and investigations have been done to determine the utility of immunotherapy for high-risk triple negative breast cancer which is known to be both clinically aggressive and, in varied clinical settings, highly resistant to standard therapeutic modalities. Results have shown clinical effectiveness of immunotherapy along with chemotherapy to demonstrate cytotoxicity in previously resistant triple negative patients. And, most intriguing are investigations by Dr. Formenti, et al on the complementary effect radiation therapy has on enhancing tumor cell kill of such patients receiving immunotherapy. Continued trials are ongoing to determine the efficacy of such immuno-radiation combination therapies.

Learning Objectives:

Presentations:

Peter Chen, MD, FACR, FASTRO, FASTRO

William Beaumont Health System

Disclosure:
Employment
Beaumont Health System, Oakld U Beaumont SOM: Staff Radiation Oncologist; Professor: Employee

Biography:
Peter Y. Chen, M.D. is a graduate of the University of Illinois College of Medicine (Chicago). He is board-certified in both internal medicine and radiation oncology. Completing his internal medicine residency at Beaumont, Immunology-Allergy Fellowship at Northwestern U and residency/fellowship in Radiation Oncology at the University of Michigan, he heads the Breast Radiation Oncology Service, co-chairs the head and neck tumor board, and actively treats patients in both the Beaumont Gamma Knife and Proton Centers. He is a Professor of Radiation Oncology at the Oakland University William Beaumont School of Medicine (OUWBSOM). As well, he serves as the Chair of the Committee of Appointments, Promotion and Tenure He has clinical subsite expertise in breast cancer (particularly accelerated partial breast irradiation (APBI), head and neck malignancies, CNS tumors (including stereotactic radiosurgical treatment using Gamma Knife), and pediatric-adolescent neoplasms. As a Fellow of the American College of Radiology (FACR) and 2018 inductee as a Fellow of the American Society for Radiation Oncology (FASTRO), he has contributed to many national research committees, chaired scientific panels on cutting-edge topics including genomics impact on the practice of breast oncology, leads clinical trials in shortened course hypo-fractionation for partial breast irradiation, and continues to contribute to the literature of radiation oncology not only as a lead author/coauthor of original articles/book chapters but also a manuscript reviewer of major peer-reviewed oncology journals. In recognition for his contributions to the specialty of Radiation Oncology, he has been honored with selection to the Best Doctors in America (2007-present), Hour Detroit Magazine’s Top Docs (2009-present) and Castle Connolly Top Doctors annually since 2016.

Presentation(s):

Send Email for Peter Chen


Assets

Panel 06 - The Evolving Role of Immunotherapy in Breast Cancer Treatment



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 06 - The Evolving Role of Immunotherapy in Breast Cancer Treatment